Preventing antibiotic associated diarrhoea using a probiotic Lactobacillus Casei preparation

2009 ◽  
Vol 47 (05) ◽  
Author(s):  
C Kamhuber ◽  
S Hörist-Kollmann ◽  
A Rek ◽  
G Eckhardt ◽  
A Zauner ◽  
...  
Keyword(s):  
Lactobacillus Casei ◽  
Probiotic Lactobacillus ◽  
Antibiotic Associated Diarrhoea

IMMUNOLOGICAL ASPECT OF ORAL ADMINISTRATION OF THE PROBIOTIC LACTOBACILLUS CASEI LB 148 UNDER COLD STRESS IN ANIMALS

2020 ◽  
Author(s):  
G.V. Kozlovskaya ◽  
◽  
M.I. Zinevich ◽  
Y.E. Kozlovsky ◽  
T.I. Khomyakova ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Oral Administration ◽  
Cold Stress ◽  
Gut Microbiome ◽  
Lactobacillus Casei ◽  
Causative Factor ◽  
Sprague Dawley ◽  
Immunological Aspect ◽  
Intestinal Lymph ◽  
Probiotic Lactobacillus

Gut microbiome changes is considered as a basic causative factor of stress-associated diseases. Probiotics are usually used for the correction of disbiosis. The aim of the investigation was the study of the effects of oral probiotic Lactobacillus casei LB 148 use onto the gut microbiota as well as the number and total square of intestinal lymph nodules of rats Sprague Dawley at in health rats and under the cold stress

The probiotic Lactobacillus casei Shirota attenuates symptoms of vestibular migraine: a randomised placebo-controlled double-blind clinical trial

2020 ◽  
Vol 11 (5) ◽  
pp. 469-476
Author(s):  
X. Qi ◽  
G. Fan ◽  
H. Jia
Keyword(s):  
Depressive Symptoms ◽  
Lactobacillus Casei ◽  
Daily Basis ◽  
Vestibular Migraine ◽  
Double Blind ◽  
Beneficial Effects ◽  
Lactobacillus Casei Shirota ◽  
Probiotic Lactobacillus ◽  
Vestibular Symptoms

Vestibular migraine (VM) has emerged as one of the major vestibular syndromes. Although probiotics have exhibited beneficial effects on migraine headache, its effect on VM is not clear. This trial aimed to investigate the treatment efficacy of the probiotic Lactobacillus casei Shirota (LcS) on symptoms of VM. 247 VM patients were enrolled, of which 204 eligible patients receiving either LcS or placebo on a daily basis completed the 4 month study. They were re-visited at 2 and 4 months after study initiation to assess treatment outcomes. The primary endpoints were vestibular symptoms, evaluated by the number of vertiginous attacks during the past week, the Vertigo Severity Score (VSS), and Dizziness Handicap Inventory (DHI) scores. The secondary endpoints were anxiety and depressive symptoms, evaluated using Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores. Efficacy of LcS over placebo was not obvious at 2 month follow-up. At 4 month follow-up, while both LcS and placebo groups of VM patients displayed alleviated symptoms, the extents of the improvements were significantly better in LcS group than those of placebo group, with regard to vestibular symptoms using DHI and VSS, as well as anxiety and depressive symptoms using BAI and BDI. Although placebo effect cannot be ignored in intervention for VM patients, the probiotic LcS still exhibits considerable efficacy against VM symptoms over a 4 month study period, supporting further clinical study of a larger and more diverse cohort.

Sign in / Sign up

Export Citation Format

Share Document